![Cover Image for System.Linq.Enumerable+EnumerablePartition`1[System.Char]](https://coverimages.igi-global.com/images/search-article.png)
Interrogating two schedules of the AKT inhibitor MK-2206 in patients with advanced solid tumors incorporating novel pharmacodynamic and functional imaging biomarkers.
Timothy A Yap, Li Yan, Amita Patnaik, Nina Tunariu, Andrea Biondo, Ivy Fearen, Kyriakos P Papadopoulos, David Olmos, Richard Baird, Liliana Delgado, Ernestina Tetteh, Robert A Beckman, Lisa Lupinacci, Ruth Riisnaes, Shaun Decordova, Simon P Heaton, Karen Swales, Nandita M deSouza, Martin O Leach, Michelle D Garrett, Daniel M Sullivan, Johann S de Bono, Anthony W Tolcher
OAI: oai:www.repository.cam.ac.uk:1810/246604
Abstract
Adult Aged Antineoplastic Agents Biomarkers Diagnostic Imaging Drug Administration Schedule Drug Monitoring Female Heterocyclic Compounds 3-Ring Humans Magnetic Resonance Imaging Male Maximum Tolerated Dose Middle Aged Neoplasm Staging Neoplasms Protein Kinase Inhibitors Proto-Oncogene Proteins c-akt Treatment Outcome